We are proud to announce the successful completion of Kariya Pharmaceuticals’ Phase I clinical trial for KP405, a brain-penetrant GLP-1/GIP analogue designed to slow the progression of Parkinson’s disease.
The study confirmed that KP405 was safe, well-tolerated, and demonstrated behaviour consistent with GLP-1 drugs previously linked to positive outcomes in both Parkinson’s and Alzheimer’s research. This is a key step forward in the development of innovative treatments for neurodegenerative diseases.
The trial delivery was described as “flawless” by Ian Laquian, CEO and Co-Founder of Kariya Pharmaceuticals, a testament to the dedication, precision, and scientific excellence that defines our approach, and an acknowledgement of the smooth and successful collaboration between our organisations.
We are proud to have conducted this important study in collaboration with Kariya Pharmaceuticals, whose scientific innovation and unwavering commitment to tackling complex neurological conditions continues to drive meaningful progress in the field.
This collaboration has been highly valued, and we are extremely proud of the joint efforts that brought KP405 one step closer to patients in need. We look forward to continuing our work together as Kariya advances its pipeline of innovative therapies.
Special recognition goes to Dr John Connell, (Chief Scientific Officer), Grace Hawes (Associate Project Director), and the wider MAC project team, whose commitment and expertise ensured the successful execution of this important trial.
MAC is proud to partner with companies like Kariya to accelerate scientific discovery and bring new therapies closer to the patients who need them most.
